| Name | Title | Contact Details |
|---|
Odonate Therapeutics™ is dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, an investigational, orally administered taxane. We are conducting our multinational, multicenter, randomized, Phase 3 study in locally advanced or metastatic breast cancer (MBC), known as CONTESSA. Our goal is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.
Actuate Therapeutics, Inc. is a private biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases leading to fibrosis and neurodegeneration.
Oncothyreon is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Also known as Advantagene. Inc., we are a Massachusetts-based biotechnology company developing our proprietary immuno-oncology platforms for the treatment of solid tumors, including our Gene Mediated Cytotoxic (GMCI™) platform and our rQNestin34.5 platform. GMCI™ is an "off-the-shelf" immunotherapy designed to generate a personalized, robust, and precise systemic response from the patient's own immune system against his or her cancer.
Gen Trak (Main) is a Liberty, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.